TB-500 vs Semaglutide
Side-by-Side Comparison
| Attribute | Tb 500 | Semaglutide |
|---|---|---|
| Category | Healing & Recovery | Metabolic / GLP-1 Agonist |
| Mechanism | TB-500 works primarily through actin sequestration — it binds to G-actin monomers, preventing premature polymerization, which allows repair cells to migrate rapidly to injured areas. | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Veterinary use in some jurisdictions. Limited human RCTs completed. | FDA-approved (Ozempic for T2D, Wegovy for obesity) |
| Safety Profile | A safety-focused RCT in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin-beta 4; No significant safety concerns in published human studies to date; TB-500 administration has produced minimal side effects in animal and human studies alike | Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient); Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness |
| Route | Subcutaneous | Subcutaneous (weekly injection); Oral tablet available (Rybelsus) |
| Dose Range | 500–1000 mcg/day SC (~5 mg/week average) | SC: 0.25–2.4 mg/week titrated over 16 weeks; Oral: 3–14 mg/day |
| Frequency | Once daily | Once weekly (SC); Once daily (oral) |
| Molecular Weight | ~889 g/mol | ~4113.6 g/mol |
| Half-Life | <2 hours plasma half-life; tissue effects persist 2–3 days | ~160–168 hours (~7 days) |
Overview
TB-500 and Semaglutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
TB-500 — Mechanism & Evidence
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found throughout human tissues. TB-500 contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. It has a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, it remains unapproved for human therapeutic use in all major markets and is banned by WADA and in horse racing.
Key claims: Accelerates wound healing; Reduces inflammation; Promotes cardiac repair.
Semaglutide — Mechanism & Evidence
Semaglutide is an FDA-approved GLP-1 receptor agonist (MW ~4113.6 g/mol, molecular formula C187H291N45O59) with 94% sequence homology to human GLP-1. It is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH (Wegovy). Developed by Novo Nordisk and first FDA-approved December 5, 2017, it is backed by the extensive STEP and SUSTAIN trial programs involving thousands of patients. There is no generic semaglutide available, and the FDA has warned about counterfeit products.
Key claims: Causes significant weight loss; Improves blood sugar control; Reduces cardiovascular risk.
Shared Research Applications
These peptides target different research areas. TB-500 focuses on Injury Recovery, Anti-Inflammatory, while Semaglutide targets Weight Management, Metabolic Health, Cardiovascular.
Safety Considerations
TB-500: A safety-focused RCT in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin-beta 4 No significant safety concerns in published human studies to date; TB-500 administration has produced minimal side effects in animal and human studies alike Common anecdotal side effects: injection site pain/redness, lightheadedness, mild headache, nausea, fatigue
Semaglutide: Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient) Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness Serious but rare: pancreatitis, gallbladder disease, severe allergic reactions (hives, swelling, difficulty breathing)
Related Products
Related Research News
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
Recent data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk even with significant weight loss. This semaglutide news adds a new dimension to GLP-1 research, with implications for metabolic and skeletal health.
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
New data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk, even with significant weight loss. The findings add a new layer to the safety profile of GLP-1 receptor agonists and have implications for peptide research.
FDA Targets Telehealth Companies Over Compounded Semaglutide Claims
The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry.